Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulforaphane for Prevention of Age-associated Cardiac and Vascular Dysfunction
NCT05408559Phase 2Withdrawn
- Sponsor
- Texas Tech University Health Sciences Center
- Start
- Jul 2022
- Primary completion
- Sep 2025
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sulforaphane in heart failure with preserved ejection fraction (HFpEF) (2 arms), sponsored by Texas Tech University Health Sciences Center. Primary endpoints: Cardiac function at 24 weeks and Functional Capacity at 24 weeks. Planned start Jul 2022; status: withdrawn.
02
Drugs
sulforaphane
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT05408559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05408559.